Jayanth Panyam

7PUBLICATIONS
8CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 27, 2026
In Vitro Characterization of Internalization Pathways and Cytotoxic Activity of Anti-HSPG2 Antibody-Drug Conjugates in MDA-MB-231-LM2 Cells.

|Nov 13, 2025
Enhancing Cancer Therapy with TLR7/8 Agonists: Applications in Vaccines and Combination Treatments.

Jagannath Mondal, Swayam Prabha, Thomas S Griffith

|Feb 09, 2021
Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC).

Vidhi Khanna, Hyunjoon Kim, Wenqiu Zhang

|May 09, 2020
TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.

Hyunjoon Kim, Vidhi Khanna, Tamara A Kucaba

|Aug 30, 2019
Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer.

Stephen Kalscheuer, Vidhi Khanna, Hyunjoon Kim

|Jan 09, 2019
Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.

Hyunjoon Kim, Vidhi Khanna, Tamara A Kucaba

Pageof 2

Frequent Collaborators

3 joint publications

David M Ferguson

2 joint publications

Hyunjoon Kim

2 joint publications

Thomas S Griffith

1 joint publications

Da Yang